After Tough Panel, A Coin Toss For BioMarin's Kyndrisa?
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceuticals Inc.'s experimental Duchenne muscular dystrophy (DMD) drug drisapersen, or Kyndrisa, if approved, got its day in court, so to speak, when it went before an FDA panel of advisers on Nov. 24, but the outcome likely was far from what the company had hoped, with the committee highly skeptical of the firm's data.